Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS-Reference-Cited by-同舟云学术

Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS

Published:2017-11-02 Issue:18 Volume:130 Page:1985-1994
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Tawara Isao¹,Kageyama Shinichi²,Miyahara Yoshihiro²,Fujiwara Hiroshi³,Nishida Tetsuya⁴,Akatsuka Yoshiki⁵,Ikeda Hiroaki⁶,Tanimoto Kazushi³,Terakura Seitaro⁴,Murata Makoto⁴,Inaguma Yoko⁵,Masuya Masahiro¹,Inoue Naoki⁷,Kidokoro Tomohide⁷,Okamoto Sachiko⁷,Tomura Daisuke⁷,Chono Hideto⁷,Nukaya Ikuei⁷,Mineno Junichi⁷,Naoe Tomoki⁴,Emi Nobuhiko⁵,Yasukawa Masaki³,Katayama Naoyuki¹,Shiku Hiroshi²

Affiliation:

1. Department of Hematology and Oncology and

2. Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan;

3. Department of Hematology, Clinical Immunology and Infectious Diseases, Graduate School of Medicine, Ehime University, Ehime, Japan;

4. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan;

5. Department of Hematology, Fujita Health University School of Medicine, Aichi, Japan;

6. Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; and

7. Takara Bio Inc., Shiga, Japan

Abstract

Key Points WT1-specific TCR-redirected T-cell therapy for AML and MDS is safe, and the T cells persisted in vivo and trafficked to bone marrow. Transient decreases of leukemic cell in bone marrow were shown.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/18/1985/1403452/blood791202.pdf

Reference35 articles.

1. Time-dependent changes in mortality and transformation risk in MDS;Pfeilstöcker;Blood,2016

2. Cancer regression in patients after transfer of genetically engineered lymphocytes;Morgan;Science,2006

3. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N Engl J Med,2011

4. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia;Inoue;Blood,1994

5. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide;Ohminami;Blood,2000

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of Wilms’ tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed;Annals of Hematology;2024-09-11

2. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome;Pharmaceutical Research;2024-08-26

3. Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors;PLOS ONE;2024-08-08

4. The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View;Cancers;2024-06-27

5. Public neoantigens in breast cancer immunotherapy (Review);International Journal of Molecular Medicine;2024-06-17